Published Date: 02 Mar 2023
DELHI: The Indian Institute of Medical Sciences (AIMS Delhi) has announced that the Professional Examination for Higher Education will be held next month.
Read Full NewsThe ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.
Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.
FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.
Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.
A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.
The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.
Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa
1.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
2.
Thriving while surviving: Understanding the social needs of cancer survivors
3.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
4.
Oncology Drug Shortages Persist, but Continue to Evolve
5.
United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.
1.
Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer
2.
The Cutting-Edge of Phlebectomy: Redefining Vein Care
3.
Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options
4.
Targeted Therapies for Breast Cancer: What’s New?
5.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation